<?xml version="1.0" encoding="UTF-8"?>
<ref id="B181-pharmaceutics-12-00171">
 <label>181.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sanchez</surname>
    <given-names>C.G.</given-names>
   </name>
   <name>
    <surname>Molinski</surname>
    <given-names>S.V.</given-names>
   </name>
   <name>
    <surname>Gongora</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Sosulski</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Fuselier</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>MacKinnon</surname>
    <given-names>S.S.</given-names>
   </name>
   <name>
    <surname>Mondal</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Lasky</surname>
    <given-names>J.A.</given-names>
   </name>
  </person-group>
  <article-title>The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis</article-title>
  <source>Arthritis Rheumatol.</source>
  <year>2018</year>
  <volume>70</volume>
  <fpage>115</fpage>
  <lpage>126</lpage>
  <pub-id pub-id-type="doi">10.1002/art.40326</pub-id>
  <?supplied-pmid 28940894?>
  <pub-id pub-id-type="pmid">28940894</pub-id>
 </element-citation>
</ref>
